Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
Second Sight Medical Products, Inc. has successfully merged with Nano Precision Medical, Inc., now rebranded as Vivani Medical, Inc., trading under the ticker VANI on Nasdaq. Following the merger, Vivani has approximately $55 million to develop products, including the NPM-119 implant for diabetes treatment and the Orion visual prosthesis for blind patients. The leadership team, led by NPM’s CEO Dr. Adam Mendelsohn, aims to tackle medication non-adherence and advance innovative therapies.